Belzutifan
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | DRUG-BELZUTIFAN |
|---|---|
| Tipo | Fármaco |
| Alegais | WeliregБелзутифан |
| Estado | reviewed 2026-04-26 | pending_clinical_signoff |
| Doenças | DIS-RCC |
| Fontes | SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Fatos sobre as drogas
| Classe | Inibidor do HIF-2α |
|---|---|
| Mecanismo | Selective small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). VHL inactivation (somatic in ~90% of clear-cell RCC, germline in von Hippel-Lindau syndrome) → HIF-2α stabilization → drives the angiogenic/glycolytic ccRCC phenotype. Belzutifan disrupts HIF-2α heterodimerization with HIF-1β, suppressing the downstream transcriptional programme. |
| Dose típica | 120 mg PO once daily, continuous, until progression or unacceptable toxicity. Hemoglobin and oxygen-saturation monitoring at baseline + every cycle — anemia + hypoxia are class-defining ON-target effects (HIF-2α regulates EPO). |
| Ucrânia registada | Falso |
| NSZU reembolsado | Falso |
| Ucrânia verificada pela última vez | 2026-04-27 |
Notas
First-in-class HIF-2α inhibitor; mechanism-of-action drug for VHL-syndrome-associated tumors. In sporadic ccRCC, used 2L+ after PD-(L)1 + VEGF-TKI. Reduces hemangioblastoma volume and pancreatic NET volume in VHL syndrome — surgery-sparing in many cases. UA-access is the bottleneck; document pathway in AccessPathway entity once Phase D content lands.
Usado por
Esquema terapêutico
REG-BELZUTIFAN-MONO- Belzutifan monotherapy (VHL-disease tumors / mRCC 2L+)